6/28/23, 11:35 PM IMbrave 150 Pathway Feedback Search Clinical Topics Home Studies IMbrave 150 IMbrave 150 Disease Hepatocellular carcinoma Trial question What is the effect of atezolizumab plus bevacizumab in patients with unresectable HCC? Study design Multi-center Open label RCT Population Characteristics of study participants 17.0% female N = 501 83.0% male 501 patients (87 female, 414 male) Inclusion criteria: patients with unresectable HCC who had not previously received systemic treatment Key exclusion criteria: history of autoimmune disease; coinfection with HBV or HCV; untreated or incompletely treated esophageal or gastric varices with bleeding or high risk of bleeding Interventions N=336 atezolizumab-bevacizumab (intravenous administration of 1,200 mg and 15 mg/kg, respectively, on day 1 of each 21-day cycle) N=165 sorafenib (at a dose of 400 mg BID, on days 1-21 of each 21-day cycle) Primary outcome Overall survival at 12 months 67.2 67.2 % 54 6 https://web.pathway.md/studies/rec4AdMf2EIHPFj0V 1/2 6/28/23, 11:35 PM IMbrave 150 Pathway 54.6 50.4 % 33.6 % Significant increase 16.8 % NNT = 8 0.0 % Atezolizumab-bevacizumab Sorafenib Significant increase in overall survival at 12 months (67.2% vs. 54.6%; AD 12.6%, 95% CI 5.12 to 20.08) Secondary outcomes Significant increase in median progression-free survival (6.8 months vs. 4.3 months; AD 2.5 months, 95% CI 1.02 to 3.98) Significant increase in confirmed objective response (27.3% vs. 11.9%; AD 15.4%, 95% CI 6.26 to 24.54) Safety outcomes No significant differences in adverse events, grade 3 or 4 adverse events. Conclusion In patients with unresectable HCC who had not previously received systemic treatment, atezolizumab-bevacizumab was superior to sorafenib with respect to overall survival at 12 months. Reference Richard S Finn, Shukui Qin, Masafumi Ikeda et al. Atezolizumab plus Bevacizumab in Unresectable Hepatocellular Carcinoma. N Engl J Med. 2020 May 14;382(20):1894-1905. Open reference URL https://web.pathway.md/studies/rec4AdMf2EIHPFj0V 2/2